The Lilly logo is seen on a wall at the unit of the Lilly France company, part of the pharmaceutical group Eli Lilly and Co, in Fegersheim, near Strasbourg, France, February 1, 2018. Photo taken on February 1, 2018. REUTERS/Vincent Kessler/ File Photo Purchase license rights
Sep 8 (Reuters) – Eli Lilly’s (LLY.N) The diabetes drug Mounjaro has won the backing of Britain’s health care profitability watchdog, which said it would be a good option for patients with poorly controlled type 2 diabetes.
The National Institute for Health and Care Excellence (NICE) said in final draft guidance that it estimates some 180,000 people could benefit from the new treatment.
The drug, also known as tirzepatide, has also been in the spotlight for its potential to treat obesity. The United States is expected to make a decision on its use for weight loss later this year. Investors have pushed Lilly’s shares higher, betting that an approval will make it a blockbuster drug.
Final NICE guidance is scheduled to be published on October 11, after which the drug will be available from the UK’s National Health Service within 90 days.
The recommendation comes after the watchdog asked Lilly in July for more data on the drug’s benefits.
Lilly did not immediately respond to a Reuters request for comment.
The charity Diabetes UK estimates that more than 5 million people in the UK are living with diabetes.
Reporting by Lavanya Ahire and Nilutpal Timsina in Bengaluru; Editing by Edwina Gibbs
Our standards: The Thomson Reuters Trust Principles.
Discover more from PressNewsAgency
Subscribe to get the latest posts sent to your email.